Status of COVID-19 vaccines in India: Four candidates in human trial stage, one in pre-clinical stage - Centre
As the threat of the possible third wave of COVID-19 looms large over India, Union Science and Technology Minister Jitendra Singh informed Rajya Sabha that four vaccine candidates are in the human trial stage while the one developed by Genique Life Sciences is in the advanced pre-clinical stage in the country.
Singh said India is one of the few countries where several COVID-19 vaccine candidates are in various stages of clinical development.
Cadila Healthcare Ltd's DNA-based vaccine candidate is in phase three clinical trial, Singh said in a written reply in Rajya Sabha. The minister further informed that the pharma company has submitted the interim data for emergency use authorisation.
The Biological E Ltd's COVID-19 vaccine candidate is in phase three clinical trials.
Bharat Biotech International Ltd's adeno intranasal vaccine candidate is also in phase three clinical trials.
Gennova Biopharmaceuticals Ltd mRNA-vaccine candidate is in phase one clinical trial.
Genique Life Sciences Pvt Ltd's vaccine candidate is in the advanced pre-clinical stage.
"The mission (Mission COVID Suraksha -- the Indian COVID-19 Vaccine Development Mission) is supporting the development of four vaccine candidates in the clinical stage of development and one vaccine candidate in advance pre-clinical stage of development.
"The clinical development of vaccine candidates is being undertaken across the clinical trial sites situated pan-India," Singh said in his written response to a question in the Upper House.
At present, Covishield developed by AstraZeneca-Oxford and manufactured by Serum Institute of India, Covaxin – the indigenous vaccine developed by Bharat Biotech and Indian Council of Medical Research (ICMR) and Russia’s Sputnik V which is being marketed by Dr Reddy’s Laboratories are being administered in India.
Notably, Moderna’s mRNA technology-based coronavirus disease (Covid-19) vaccine has been given the green signal for restricted use that is commonly known as emergency use authorisation in India. Indian pharmaceutical company Cipla had applied for permission to import the vaccine.
Notably, the government on Tuesday said that around 40 crore people are still vulnerable to coronavirus infection even as a serosurvey conducted by the Indian Council of Medical Research (ICMR) has found 67.6 per cent of people have COVID-19 antibodies.